Deal-Making

Lonza joins the race for weight loss drugs with plans to produce an active pharmaceutical ingredient (API) for Iconovo’s intranasal biologic.

Deal-Making

Contract development and manufacturing organization (CDMO) Samsung Biologics will provide manufacturing services for the client in what it calls its ‘largest ever contract’.

Facilities & Capacity

Company experts pointed to fast turnaround time as key to successfully launching a new autologous therapy in 2026.

Therapeutic Class

The CEO of CRISPR Therapeutics gave attendees a peek into the future of off-the-shelf gene therapies at the JP Morgan conference in San Francisco, California.

Global Markets

Contract development and manufacturing organization (CDMO) Samsung Biologics will provide manufacturing services for the client in what it calls its ‘largest ever contract’.

Facilities & Capacity

Indian CDMO Aragen has laid out aggressive expansion plans for capacity and multi-modality services following a $100 million investment from Singapore-based private equity (PE) fund Quadria Capital.

Regulations

With BIOSECURE in limbo, the US government seeks other ways to protect American interests.

Facilities & Capacity

Indian CDMO Aragen has laid out aggressive expansion plans for capacity and multi-modality services following a $100 million investment from Singapore-based private equity (PE) fund Quadria Capital.

Therapeutic Class

Scaling capacity takes center stage at JPM as Thermo Fisher’s CEO navigates evolving pharma landscape and policy shifts.

Therapeutic Class

Company experts pointed to fast turnaround time as key to successfully launching a new autologous therapy in 2026.

Upstream & Downstream Processing

With BIOSECURE in limbo, the US government seeks other ways to protect American interests.

Therapeutic Class

Company experts pointed to fast turnaround time as key to successfully launching a new autologous therapy in 2026.